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Abstract: Ovarian cancer is a malignant tumor that seriously threatens the safety of 
women's life. Chemotherapy is an important treatment for ovarian cancer. Although 
the initial response rate of ovarian cancer patients to chemotherapy is high, most 
patients will still relapse and die. After a first-line chemotherapy of paclitaxel and 
platinum drugs, a study has shown that after chemotherapy, the initial response rate in 
advanced patients is as high as 80%, but 70% to 80% of patients eventually relapse. 
Although the chemotherapy regimen of ovarian cancer has been improved, the 
efficacy of ovarian cancer has not been fundamentally improved, The 5-year survival 
rate is still at 30% to 45%. The ubiquitous phenomenon of chemotherapeutic drug 
resistance is the central link that leads to the failure of chemotherapy and the 
improvement of survival rate. How to solve the problem of chemotherapeutic drug 
resistance in ovarian cancer is one of the difficulties in the treatment of ovarian cancer 
at present. The high frequency of tumor cell resistance suggests the occurrence of 
specific molecular mechanisms within the tumor, Using second-generation 
sequencing technology to detect tumor-specific molecular changes in the blood 
circulation. The real-time and dynamic detection of the whole genome information of 
tumor has broad application prospects in exploring the molecular mechanism of tumor 
drug resistance recurrence and transforming ctDNA from basic research to clinical 
application. 
 
Key words: second-generation sequencing NGS, ctDNA, ovarian cancer, drug 
resistance relapse 
 
Ovarian cancer is a malignant tumor that seriously threatens the life safety of women, 
and its fatality rate is the first in female genital malignant tumors. Because of the early 
clinical symptoms and signs are relatively hidden and not easy to detect, and due to 
the lack of effective screening methods, frequently, most of the 70% of the patients 
are late at the time of medical treatment, accompanied by pelvic and abdominal 
metastases optically. At present, the principle of treatment for advanced ovarian 
cancer is operation, combined with chemotherapy, radiotherapy and other 
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comprehensive treatment, of which platinum based chemotherapy is a major adjuvant 
therapy for advanced ovarian cancer. But even as the most commonly used first-line 
chemotherapy drug, its primary or secondary drug resistance is a major obstacle to the 
treatment of ovarian cancer, it is also one of the main reasons that the five - year 
survival rate of patients with advanced ovarian cancer is difficult to exceed 30%. 
After the initial treatment of ovarian cancer patients, about 70%-80% of the patients 
have a recurrence. The recurrence of ovarian cancer is defined as a relatively short 
duration of chemotherapy, which occurs within 6 months. However, for patients with 
drug-resistant recurrent ovarian cancer, platinum based chemotherapy can not be 
continued, the choice of drugs is less, the treatment is difficult, the survival period is 
short, and the prognosis is poor. Therefore, to find out the causes of platinum 
resistance in ovarian cancer is the problem that we need to solve urgently. It is also the 
precondition for rational selection of effective drugs for ovarian cancer. In recent 
years, studies have shown that the heterogeneity of tumor plays a very important role 
in the drug resistance of ovarian cancer [1]. 
 
Tumor heterogeneity is an important manifestation of tumor recurrence and metastasis, 
and it is also the main restriction of tissue biopsy[2,3].The heterogeneity of tumor 
shows that the same tumor shows different genetic characteristics in different 
regions(namely, intratumoral heterogeneity). Similarly, heterogeneity exists in 
metastatic tumor of the same patient(namely, transfer heterogeneity) [1]. Because the 
tumor is heterogeneous, so the pathological tissue obtained by surgery or biopsy can 
only reveal the genetic information of tumor unit point, and can not fully reveal the 
biological characteristics and dynamic changes of tumor, and then it will affect the 
selection of the clinical treatment plan and the accuracy of the evaluation of the 
curative effect. Circulating tumor DNA ( ctDNA), also known as liquid biopsy, can 
remedy the defect of tissue biopsy, it reflects the changes of blood circulation in 
patients with tumor genomic information rather than unit information, break through 
the tumor heterogeneity constraints, it provides technical possibility for real-time and 
dynamic monitoring of tumor whole genome information [4]. 
 
1. The characteristics and application of ctDNA 
Although tumor tissue is the gold standard for clinical and research sequencing, it is 
still difficult to obtain and apply the tissue. From the perspective of sampling, biopsy 
is not a simple method. In addition, biopsy increases the cost of nursing and makes 
the patient feel sick, but this invasive examination will not affect the result. The last 
and most important point is that a biopsy may have a clinical complication. The MD 
Anderson cancer center report showed that the incidence of adverse events in trachea 
biopsy and abdominal and pelvic biopsy was 17.1% and 1.6%, respectively[5]. 
 
In addition to the problem of tissue acquisition, the use of tumor tissue for gene 
sequencing is also affected by the problem of sample preservation and the problem of 
tissue heterogeneity. Most of the tumor tissues are preserved in formalin fixed paraffin 
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embedded blocks, and are cross-linked with DNA. In some cases, the preserved 
samples can not be adequately analyzed in molecular analysis. Although this approach 
has been improved in single gene mutations and target gene sets, there are still 
limitations in the full genome exon analysis. In addition, the number of cancer cells in 
each biopsy is different, largely influenced by the density of the tumor cells (the 
percentage of the tumor) and the size of the sample required, the number of cancer 
cells is also affected by the number of tissues in fine needle aspiration or thick needle 
biopsy. Compared with the samples removed during operation, the number of tumor 
tissue obtained by puncture is small.  
 
Biopsy or partial tissue section of a single tumor will lose heterogeneity and 
metastasis in the tumor. In theory, circulating tumor DNA (ctDNA) can provide the 
same genetic information as tissue biopsy. CtDNA is a class of double stranded DNA 
fragments with a size of 0.18~21kb. They originate from tumor cells. They mainly 
exist in the blood of tumor patients, synovial fluid and cerebrospinal fluid, and can be 
excreted by patients' urine and feces. CtDNA, also known as "liquid biopsy", can 
reflect the whole picture of tumor genome information, so it can break through the 
restriction of tumor heterogeneity. On the other hand, it is a source of fresh DNA, not 
affected by preservatives. Using a minimally invasive technique, a needle tube is used 
to sample blood to avoid the risk of biopsy. In addition, during the period of treatment, 
blood can be extracted at any time to dynamically monitor the molecular changes in 
the tumor[6,7,8]. The ctDNA fragment contains the same genetic defects as the tumor 
itself. These DNA changes include all types of genomic alterations in the tumor, such 
as point mutations (EGFR and KRAS), rearrangement (EML4-ALK), gene 
proliferation (HER2 and MET) and aneuploidy[1]. 
 
As a dynamic marker of tumor, ctDNA has more advantages than traditional protein 
markers and imaging examinations. The half-life period of ctDNA is short (about 2 
hours), so it can respond to a few hours of tumor changes rather than weeks or 
months[9]. Therefore, the change of ctDNA is a few weeks or even a few months 
earlier than the imaging examination or the protein marker[10]. Furthermore, protein 
markers, such as CA125, are not only elevated in patients with malignant tumors, but 
also in benign tumors and inflammation. Another feature of ctDNA is highly sensitive. 
Studies have shown that the sensitivity of liquid biopsies in patients with stage IV 
tumors is nearly 100%[11]. Although the sensitivity of ctDNA is high in advanced 
cancer, it must be clear that the sensitivity of ctDNA is mainly influenced by 
biological and technical factors. When there is a low grade tumor or a small 
metastasis, the content of ctDNA is also reduced. In strict sense, the sensitivity of 
ctDNA detection is also limited by the DNA polymerase error rate (usually 0.01%). 
Therefore, if the error rate of the ctDNA fragment in the sample is less than or equal 
to 0.01%, then the ctDNA can be considered negative. Another important advantage 
of ctDNA analysis is highly specific, which can be used to detect tumor specific 
molecular changes in the blood circulation. Because the ctDNA mutation is targeted 
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to the tumor individual and exists in the tumor DNA, it does not appear in the normal 
cell DNA. Because of its high sensitivity and specificity, ctDNA can be used for 
molecular heterogeneity assessment, monitoring tumor dynamics, identifying gene 
therapy factors, tracking the evolution of genome and development of drug resistance. 
Therefore, it has a broad application prospect in exploring the molecular mechanism 
of tumor recurrence and metastasis and drug resistance[1]. 
 
2. Clinical application of using NGS to detect ctDNA in tumor 
The application of high-throughput gene sequencing (NGS) detection technology can 
detect ctDNA content in body fluid, so that we can get driving gene information for 
tumor mutation and cancer cell specific antigen, and then discover a new generation 
of biomarkers. With the research of tumor genome, more and more tumor related 
genome information has been discovered. Now we know that almost all kinds of 
cancers are related to gene mutation in somatic cells. These types of mutation include 
single base replacement, insertion mutation, deletion mutation and chromosome 
translocation (gene fusion, gene amplification, loss of heterozygosity). In the whole 
cell population, the mutation frequency of these somatic cells is very low, so it can be 
used as a specific biomarker from a biological perspective[12]. 
 
[Early diagnosis] 
In a Bettegowda study, gene mutations could be detect from all 410 cancer patients , 
which made ctDNA a further biomarker for cancer patients. In addition, the level of 
ctDNA detected in over 80% of metastatic tumor patients is much higher than other 
traditional biomarkers, such as protein markers CA125, CEA and so on. Unlike 
protein markers, gene mutation occurs only in tumor cells, but protein markers are not 
only found in tumor cells, but also in normal cells[13]. 
 
A recent study showed that plasma ctDNA integrity in the value of early diagnosis of 
breast cancer, the concentration of ctDNA combined with CFDI (cell-free integrity) ) 
has important value in early diagnosis of primary breast cancer (PBC) and metastatic 
breast cancer ( MBC) . The study was carried out in 383 patients with breast cancer, 
including 82 cases of PBC and 201 cases of MBC and 100 healthy controls. The 
results showed that ctDNA concentration combined with CFDI can well distinguish 
primary breast cancer, metastatic breast cancer and healthy controls[14]. 
 
In 2013, the study of colorectal cancer patients by Da and other scholars showed that 
the value of plasma CFDI was of great significance in the diagnosis of colorectal 
cancer.The study included 27 cases of non operation treatment for patients with 
colorectal cancer, 33 cases of patients with colorectal cancer and 33 healthy controls, 
the results showed that the differences of CFDI value of plasma in operation group 
and non operation group, operation group and health control group, non operation 
group and healthy control group were all of statistical significance[15].  
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In addition, Leszinski et al.[16] showed that in the diagnosis of colon cancer, the 
integrity of ctDNA is valuable in the results of the 2014 study.  
 
[Monitor tumor burden and determine prognosis] 
CtDNA can also monitor the changes of tumor load in real time, dynamically and 
noninvasive, so it can be used as a new biomarker in clinical research. The study 
results of Luis et al. show that the detection of ctDNA in metastatic tumor patients can 
guide the clinical treatment, can monitor the recurrence of the tumor and suggest the 
prognosis. For example, the low level of ctDNA in patients with metastatic colorectal 
cancer (CRC) indicates a good prognosis. This conclusion indicates a correlation 
between ctDNA concentration and survival rate. The same conclusion also appears in 
the study of patients with advanced breast cancer[1]. In addition, in a case-control 
study of gastric cancer, the researchers compared the changes of plasma ctDNA levels 
before and after operation. The results showed that plasma ctDNA levels were 
significantly lower than those before operation. Therefore, it is concluded that ctDNA 
quantification can be used to evaluate the completeness of surgical resection for tumor 
patients, that is, the more complete surgical resection is, the lower the ctDNA content, 
and the ctDNA quantification can also prompt the metastasis and recurrence of the 
tumor very early[17].  
 
In addition, many studies have shown that ctDNA can also be used to judge the 
prognosis of cancer patients with high accuracy. A study by Lecomte et al. explored 
the value of the K-ras gene mutation in the peripheral blood ctDNA and 
hypermethylation of the CDKN2A promoter in the prognosis of colorectal cancer, in 
this study, 37 patients with colorectal cancer were followed up for an average of 22 
months and the survival analysis was performed. The results showed that the 2 year 
overall survival rate (48%, 95% CI 26%~66%) of K-ras gene mutation and CDKN2A 
promoter hypermethylation was significantly lower than the overall survival rate 
(100%) of patients without the above gene mutation. COX regression analysis showed 
that ctDNA K-ras gene mutation and hypermethylation of CDKN2A promoter was an 
independent prognostic factor of CRC. This result further illustrates the important 
value of K-ras gene mutation or CDKN2A promoter hypermethylation in the 
prognosis of CRC patients, and is also expected to become a biomarker for predicting 
the recurrence risk of CRC patients. In a study published in 2012, a high level of 
K-ras gene mutation was found to be associated with a poor prognosis of CRC. In this 
study, 108 patients with metastatic CRC were treated with cetuximab combined with 
irinotecan, and the levels of K-ras and BRAF mutations in plasma ctDNA were 
quantitatively detected before treatment. The results showed that the disease control 
rate of patients with K-ras mutation level above 75% was significantly lower than that 
of the low level mutation patients (P<0.048). Cox regression analysis showed that the 
mutation level of K-ras gene in ctDNA was significantly correlated with the prognosis 
of metastatic CRC. The prognosis of CTC patients with a high level of K-ras gene 
mutation is poor[18]. A similar report was also reported in a study on changes in 
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plasma ctDNA in patients with metastatic breast cancer in 2013 by Dawson et al.[19]. 
 
[Evaluation of efficacy and detection of drug resistance in time] 
In recent years, many scholars are committed to the study of monitoring ctDNA 
specific gene alterations in peripheral body fluid, such as gene mutation types and 
copy number variations, so as to achieve the purpose of curative effect evaluation. For 
example, in a study of metastatic breast cancer, the results showed that ctDNA could 
reflect disease progression and therapeutic effect earlier than circulating tumor cells, 
carbohydrate antigen 153 (CA153) and imaging examination[19]. In another study of 
metastatic breast cancer and ovarian cancer, plasma samples were used to track the 
dynamic changes of tumor specific mutation genes. The results showed that ctDNA 
could reflect the clinical course of disease[20].  
 
Some patients with tumor targeted therapy can acquire acquired resistance. For 
example, in a study by Diaz[21] et al., the ctDNA was esed to monitor the related 
mutation genes and evaluate the efficacy of targeted therapy. The researchers found 
that for K-ras wild type patients with metastatic CRC, some of them still have some 
resistance after targeted therapy with panitumumab. After testing the ctDNA of these 
patients, it was found that the K-ras gene mutation appeared in the form of low 
frequency subclones before treatment, and at a follow-up of 5 to 6 months later, 38% 
of the K-ras mutation was found in the ctDNA of the population, and a new mutation 
of the BRAF gene was found in 9 patients. The results showed that by monitoring the 
changes in gene spectrum of ctDNA targeted therapy, we could evaluate the efficacy 
of targeted therapy, and adjust the selection of drugs based on this basis in clinical 
treatment. And at present, compare the body fluid ctDNA to the tumor tissue DNA, 
the sensitivity, specificity and consistency of the detection of specific gene changes 
are still lacking a unified conclusion and need to be further verified by clinical data. 
The research of Hickey et al. have detected ctDNA in serum and ascites of ovarian 
cancer patients. The results show that some molecular variants are closely related to 
the clinical stage, curative effect evaluation and prognosis of patients. Song Xu et al. 
reported that using NGS to detect ctDNA in tissue samples and matched blood 
samples in advanced lung cancer, the agreement rate could reach 76.2%[22]. Evelyn 
Kidess[23] et al detected 46 genes in colorectal cancer patients and compared the 
consistency of four genes such as KRAS/PIK3CA/BRAF/EGFR. The agreement rate 
of 19 patients with stage IV was 93%, and the agreement rate of 19 patients with stage 
I-III reached 54. %, however, JiaCheng Tang[24] et al. reported that gene detection of 
tissue DNA and humoral ctDNA in liver cancer patients showed that the specificity, 
sensitivity, and consistency of the samples were very different.  
 
3. Analysis of genetic biological information of patients with drug-resistant recurrent 
ovarian cancer 
 
The recurrence of drug-resistant ovarian cancer may be caused by a variety of factors, 
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including changes in the patient's own and the changes in the gene of the tumor 
cells.This is the most serious problem in the treatment of cancer. The high frequency 
of cancer cell resistance suggests the occurrence of special molecular mechanisms in 
the tumor. Oncogenes are abnormal forms of proto-oncogenes during cell growth and 
differentiation. When activated by specific point mutations, chromosome shifts, gene 
amplification, or other mechanisms, proto-oncogenes may be transformed into 
oncogenes that can lead to abnormal proliferation of cells or stimulate abnormal cell 
survival by interfering with apoptosis. At present, many studies have made a 
comprehensive assessment of the important role of oncogene in the development of 
ovarian cancer[25]. 
 
It has been reported that multidrug resistance of ovarian cancer may involve CXCR4, 
NRP1, ACO1, BDNF and HMGCR. 5 up-regulated genes and CDKN2C, FAS, SKP2, 
and 3 down regulated expression genes[26]. CXCR4 encoding chemokine receptor 4 
(chemokine receptor 4), the receptor ligand stromal cell-derived factor -1 (stromal cell 
derived factor-1, SDF-1) specific binding, play an important role in tumor cell 
proliferation, invasion and migration, and to participate in the progression and 
prognosis of tumor. In the research of Kwong, CTCE-9908 (CXCR4 receptor 
antagonist) treatment and paclitaxel in patients with ovarian cancer, the results show 
that a combination of drugs can induce ovarian cancer cell mitosis disorder, increase 
cell toxicity, therefore concluded that CXCR4 is expected to become a new target for 
ovarian cancer therapy[27]. NRP1 is a receptor of vascular endothelial growth factor 
(VEGF), and it is a potential anti-tumor therapeutic target for many kinds of human 
malignant tumors. NRP1 can promote the self-renewal ability of cancer stem cells. Its 
high expression in cancer tissues will seriously affect the prognosis of patients, and it 
is of great significance in the development of ovarian cancer[28]. The over expression 
of NRP1 in cancer tissues seriously affects the prognosis of patients. It is a potential 
anti-cancer therapeutic target of human multiple malignancies including ovarian 
cancer[29,30]. Other studies have reported that AKT1, AKT2, BAX, EGFR, JUN, 
MYC, NFKB1, PIK3CA, RAS, and SRC are key regulators of ovarian cancer 
resistance. AKT and BAX is a downstream gene in a number of oncogene mediated 
ovarian cancer resistance pathways and plays a central role. 
 
Multidrug resistance in ovarian cancer often involves many factors, such as signal 
transduction, metabolic pathways, protease pathways, and DNA damage and repair. 
Some signaling pathways such as MAPK, PI3K/AKT and BAX activate [31, 32,33], 
or some signaling pathways such as P53 inactivation [34,35], which may also affect 
cell growth, proliferation, differentiation and apoptosis, and then form multidrug 
resistance of ovarian cancer. This article will briefly introduce and summarize these 
signal paths. 
 
【MAPK】 
Many studies have confirmed that MAPK signaling pathway is closely related to 
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chemotherapeutic drug resistance in ovarian cancer. At present, the MAPK family has 
been found to include 8 subgroups, such as ERK, ERK3, ERK5/BMK1, ERK7, ERK8, 
JNK, NLK, P38 MAPK, etc. In epithelial ovarian cancer, the dose of platinum drugs 
is closely related to the continuous activation of ERK1/2 and JNK. The continuous 
activation of ERK1/2 and JNK can induce DNA damage and apoptosis. However, the 
continuous activation of ERK1/2 and JNK signals can also induce the production of 
platinum resistance in ovarian cancer cells. Conversely, the sensitivity of ovarian 
cancer cells to platinum drugs can be enhanced by inhibiting the continuous activation 
of ERK1/2 signals, [32,33]. It is also suggested that the activation of ERK1/2 pathway 
and the inactivation of the P38MAPK pathway can induce the resistance of ovarian 
cancer cells to platinum drugs. In addition, MAPK1, also known as ERK, is 
considered to be involved in [31] in the MAPK1 mediated MAPK signaling pathway 
associated with ovarian cancer resistance. 
 
【PI3K/AKT】 
The mechanism of drug resistance in ovarian cancer is to stimulate cell survival and 
block apoptosis. PI3K/AKT signaling pathway is the main pathway for cancer cells to 
survive. AKT can be activated by various stimuli, such as growth factors, protein 
kinase inhibitors, etc. For example, the expression of ACTN4 mRNA can increase the 
phosphorylation of AKT and stimulate AKT shift and cell proliferation. PTEN is a 
negative regulating factor of the PI3K/AKT pathway. The decrease of PTEN can also 
lead to the increase and activation of AKT phosphorylation, thereby promoting cell 
survival and proliferation, blocking cell apoptosis, and eventually leading to the 
occurrence of platinum resistance. 
 
【BAX】 
BAX is a cell death stimulator and homologous to anti apoptotic BCL2 protein. BAX 
and BCL2 or BCL2-like 1 (BCL-XL, also known as BCL2L1), can form 
heterozygous two polymers. BAX-mediated apoptosis depends on the relative amount 
of BAX, that is, whether BCL2 and/or BAX:BCL-XL heterodimers appear in cells. If 
heterodimers appear, the amount of BAX decreases. BAX-mediated apoptosis is 
reduced. The apoptosis pathway induced by BAX is a necessary pathway for 
chemotherapy induced cell death, so the down-regulation of BAX is closely related to 
chemotherapeutic drug resistance. Besides, BAX is also a downstream gene of 
multiple ovarian cancer resistance related genes. These results show the important 
role of BAX and AKT in the drug resistance of ovarian cancer [31]. 
 
【tp53】 
P53 is a tumor suppressor gene involved in inducing cell cycle arrest, promoting 
apoptosis and DNA repair. Many studies have confirmed that P53 signaling pathway 
is associated with the pathogenesis and prognosis of ovarian cancer, and the 
sensitivity of platinum chemotherapy is closely related to the functional status of P53 
[36,37]. The P53 gene regulatory network (P53 signaling pathway) is first proposed 
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by Vogelstein et al in 2000. It is pointed out that cell life activity is regulated by gene 
interaction in P53 gene regulatory network. Among them, 
MDM2-P53-P21WAF1/CIPI is the most important pathway in the P53 signaling 
pathway, and any abnormal gene in this pathway may lead to the occurrence of tumor. 
 
Apoptosis and phosphorylation are the two most important biological pathways of 
oncogene resistance to ovarian cancer [31]. Apoptosis is an inseparable part of the 
physiological balance, and the relationship between apoptosis and resistance depends 
on who is more dominant in the process of cell proliferation and differentiation. For 
example, the oncogene BCL2, a negative regulator of apoptosis, is a contribution to 
drug resistance by reducing apoptosis. DOK2 can induce carboplatin resistant in 
ovarian cancer by inhibiting apoptosis [36]. Phosphorylation and dephosphorylation 
can regulate the signal transduction of growth factors and cytokines, thereby 
regulating cell reproduction, differentiation, survival and apoptosis, and the 
occurrence and development of cancer[37]. The expression of many genes associated 
with ovarian cancer resistance is also regulated by phosphorylation, such as AKT, 
SRC, and STAT3[38]. In addition, the activation of other pathways, such as mismatch 
repair, can also induce the production of chemotherapeutic drug resistance in ovarian 
cancer. 
 
【BRCA2】 
BRCA2 gene is an oncogene. There is an important relationship between inhibition, 
carcinogenesis and prognosis is located in 13q12-13, a group of ovarian cancer and 
breast cancer. The genomic DNA is about 70kb, encoding 10987bp, and has 27 exons. 
The eleventh exon is the largest exon. It is the site of binding with DNA repair related 
protein 51 (DNA damage repair protein 51, RAD 51). The mRNA of BRCA2 is about 
10 kb long and encodes a tumor-inhibitory BRCA2 protein consisting of 3418 amino 
acid residues. 
 
BRCA2 is closely related to RAD51 in homologous recombination[40] and DNA 
damage repair function together. At the end of the carboxyl group of BRCA2, there is 
a domain called the BRCA2 DBD (DNA/DSS1-binding domain) domain, which 
contains 5 domains similar to the DNA binding motifs: Screw, OB1, OB2, OB3 
domain and domain tower. When the BRCA2 mutation in the tumor, 5 missense 
domain mutation incidence rates were 25%, 25.4%, 8.6%, 8.6% and 32.4%. When the 
DNA double strand damage, DNA damage will send a signal, the signal will be 
further activated such as ataxia telangiectasia gene (ataxia-telangiectasiamutated, 
ATM), antithrombin (antithrombin receptor, ATR) receptor like kinase activity in the 
catalytic BRCA2/RAD51 phosphorylation of  protein complexes [8]. The 
transformation from inactive form into an active form, and then, the BRCA2 protein 
carrying RAD51 protein transport to the common double strand DNA damage sites 
involved in the reorganization of double strand DNA damage repair, play the role of 
tumor suppressor. 
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BRCA2 mutant cells have homologous recombination function defects, and DNA 
damage can also cause insufficient aggregation of RAD51 nuclei. DNA repair defects 
can produce another result, which is highly sensitive to the widely used anticancer 
drug DNA injuring agent. DNA damaging agents have a prominent role in DNA 
repair-defective tumor cells [41]. BRCA2 mutation in patients with ovarian cancer 
were sensitive to platinum, but at the end of this part of patients will still become 
platinum resistance. 
 
The present study suggests that the Second mutation of some tumor suppressor genes 
carrying primary tumor may be related to the acquired platinum resistance, such as 
TP53, breast cancer susceptibility gene 1 and 2 (BRCA1 and BRCA2), such as TP53, 
breast cancer susceptibility genes 1 and 2 (BRCA1 and BRCA2). Studies have shown 
that in BRCA1 and BRCA2 ovarian cancer carrying the reading frame shift mutation, 
the acquired platinum resistance is produced by two mutations in the gene. Corrected 
the Open Reading Frames (ORF) of mutant BRCA1/2, restored the expression of wild 
type BRCA1/2 and DNA homologous recombination repair function, which led to the 
occurrence of acquired platinum resistance in ovarian cancer. In the cell line of 
pancreatic cancer or ovarian cancer with BRCA2 mutation, the two mutation of 
BRCA2 can be induced by cisplatin or polyadenosine two phosphate ribose 
polymerase (poly ADP-ribose polymerase (PARP) inhibitor)[42]. As a result of this 
reverting mutation, the truncated BRCA2 protein is renewed and carries the function 
of homologous recombination. So, the BRCA2 mutation occurred two times the use 
of platinum drugs in BRCA2 mutant tumors is acquired. The mechanism of resistance 
to platinum. 
 
BRCA2 makes DNA damage repair function missing, and cell genetic instability 
increases the incidence of ovarian cancer, and ovarian cancer is sensitive to platinum 
based DNA damage agents, after the two mutation of BRCA2, in the BRCA2 ovarian 
cancer carrying frameshift mutation, corrected the open reading frame of the mutant 
BRCA2, restored the expression of wild type BRCA2 and DNA homologous 
recombination repair function, which led to the occurrence of acquired platinum 
resistance in ovarian cancer. However, the current BRCA2 two gene mutation induced 
resistance in ovarian cancer is not very clear. 
 
In summary, chemotherapy is an important treatment for patients with ovarian cancer. 
Although the initial ovarian cancer patients curative effect is high, studies have 
pointed out that after paclitaxel and platinum drugs such as first-line chemotherapy in 
patients with advanced initial reaction rate as high as 80%, the complete remission 
rate of 40%~60%, but the majority of patients will relapse and death, the data showed 
that 70%~80% patients with recurrence, 5 years survival rate is still around 30%~45%. 
The main factor which leads to the failure of chemotherapy and the improvement of 
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survival rate is the emergence of chemotherapeutic drug resistance[26]. Therefore, it 
is an urgent problem to find an effective way to solve the drug resistance of 
chemotherapy. 
 
Using NGS detection technique, the tumor specific molecular changes can be detected 
in the blood circulation, and the whole genome information of tumor can be detected 
in real time and dynamically. Therefore, it has broad application prospects in 
exploring the molecular mechanisms of tumor recurrence, metastasis and drug 
resistance. The emergence of this technology is in line with the current trend of 
“precise medical care” in the current tumor. Therefore, the molecular mechanism of 
ctDNA analysis of the drug resistance of ovarian cancer by NGS technique may open 
a new situation for the treatment of patients with recurrent ovarian cancer. 
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